Effects of Guizhi decoction for diabetic cardiac autonomic neuropathy: a protocol for a systematic review and meta-analysis

Chen, Junmin; Cai, Jiawei; Wei, Mengya; Zhang, Xiaoran; Zhong, Min; Liu, Min; Qiu, Chen

doi:10.37766/inplasy2020.8.0018

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, we found that GZD significantly improved heart rate variability and vagus nerve activity, which are associated with the progression of hypertension [10]. A meta-analysis confirmed the beneficial effect and safety of GZD in the treatment of diabetic cardiac autonomic neuropathy [12]. Zheng et al reported that GZD associated formulas exerted significant effects on the attenuation of moderate-severe painful diabetic peripheral neuropathy [13].…”

Section: Introductionsupporting

confidence: 64%

“…GZD is wildly used to treat many internal diseases, including allergic or respiratory diseases, endocrine system disease, nervous system disease, and cardiac autonomic neuropathy [25]. Additionally, GZD has accumulated plentiful experiences in the treatment of cardiovascular diseases, such as hypertension [11,12,26]. However, its material basis and potential mechanisms have not been fully elucidated.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential mechanisms of Guizhi decoction against hypertension based on network pharmacology and Dahl salt-sensitive rat model

et al. 2021

View full text Add to dashboard Cite

Background Guizhi decoction (GZD), a classical Chinese herbal formula, has been widely used to treat hypertension, but its underlying mechanisms remain elusive. The present study aimed to explore the potential mechanisms and therapeutic effects of GZD on hypertension by integrating network pharmacology and experimental validation. Methods The active ingredients and corresponding targets were collected from the Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP). The targets related to hypertension were identified from the CTD, GeneCards, OMIM and Drugbank databases. Multiple networks were constructed to identify the key compounds, hub targets, and main biological processes and pathways of GZD against hypertension. The Surflex-Dock software was used to validate the binding affinity between key targets and their corresponding active compounds. The Dahl salt-sensitive rat model was used to evaluate the therapeutic effects of GZD against hypertension. Results A total of 112 active ingredients, 222 targets of GZD and 341 hypertension-related targets were obtained. Furthermore, 56 overlapping targets were identified, five of which were determined as the hub targets for experimental verification, including interleukin 6 (IL-6), C–C motif chemokine 2 (CCL2), IL-1β, matrix metalloproteinase 2 (MMP-2), and MMP-9. Pathway enrichment analysis results indicated that 56 overlapping targets were mainly enriched in several inflammation pathways such as the tumor necrosis factor (TNF) signaling pathway, Toll-like receptor (TLR) signaling pathway and nuclear factor kappa-B (NF-κB) signaling pathway. Molecular docking confirmed that most active compounds of GZD could bind tightly to the key targets. Experimental studies revealed that the administration of GZD improved blood pressure, reduced the area of cardiac fibrosis, and inhibited the expression of IL-6, CCL2, IL-1β, MMP-2 and MMP-9 in rats. Conclusion The potential mechanisms and therapeutic effects of GZD on hypertension may be attributed to the regulation of cardiac inflammation and fibrosis.

show abstract

Section: Introductionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 99%